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A B S T R A C T
Successful immunization often requires a primer, and after a certain lag time, a booster administration of the
antigen. To improve the vaccinees’ comfort and compliance, a single-injection vaccine formulation with a bi-
phasic pulsatile release would be preferable. Previous work has shown that such a release proﬁle can be obtained
with compacts prepared from physical mixtures of various poly(DL-lactic(-co-glycolic) acid) types (Murakami
et al., 2000). However, the mechanism behind this release proﬁle is not fully understood. In the present study,
the mechanism that leads to this biphasic pulsatile release was investigated by studying the eﬀect of the glass
transition temperature (Tg) of the polymer, the temperature of compaction, the compression force, the tem-
perature of the release medium, and the molecular weight of the incorporated drug on the release behavior.
Compaction resulted in a porous compact. Once immersed into release medium with a temperature above the Tg
of the polymer, the drug was released by diﬀusion through the pores. Simultaneously, the polymer underwent a
transition from the glassy state into the rubbery state. The pores were gradually closed by viscous ﬂow of the
polymer and further release was inhibited. After a certain period of time, the polymer matrix ruptured, possibly
due to a build-up in osmotic pressure, resulting in a pulsatile release of the remaining amount of drug. The
compression force and the molecular weight of the incorporated drug did not inﬂuence the release proﬁle.
Understanding this mechanism could contribute to further develop single-injection vaccines.
1. Introduction
Annually, vaccination prevents approximately 2–3million deaths
caused by more than thirty diﬀerent infectious diseases (Kardani et al.,
2016; WHO, 2018). Successful vaccination, i.e. providing protection by
creating pools of long-term memory B- and T-cells, often requires a
primary (primer) and after a certain lag time, a secondary (booster)
administration of the vaccine (McHeyzer-Williams and McHeyzer-
Williams, 2005; Siegrist, 2013). Hence, most traditional vaccines are
administered using a multi-injection regime (McHugh et al., 2015). This
multi-injection regime is discomforting for the vaccinee and might
compromise compliance (Cleland, 1999; McHugh et al., 2015). Im-
proved vaccinees’ comfort and compliance would be achieved with an
injectable device with a biphasic pulsatile release proﬁle. Such an im-
plant releases one part of the antigenic substance instantly (primer),
while the remainder is released after a certain lag time (booster)
(Cleland, 1999; McHugh et al., 2015). Ideally, this lag time can be
tailored to the requirements of the speciﬁc antigen that is used.
Previous work on the development of such a single-injection vaccine
has shown the use of various polymers (Cleland, 1999). Of these
polymers, poly(DL-lactic(-co-glycolic) acid) (PL(G)A) is most widely in-
vestigated. PL(G)A is a biodegradable and biocompatible copolymer
that has been used in many drug products approved by the Food and
Drug Administration (Fredenberg et al., 2011a; Makadia and Siegel,
2011). The copolymer consists of lactic and glycolic acid monomers. By
changing the lactic:glycolic acid ratio of the copolymer, physicochem-
ical characteristics (e.g. glass transition temperature (Tg) and de-
gradation rate) of the polymer can be tailored (Fredenberg et al.,
2011a; Makadia and Siegel, 2011; Xu et al., 2017). Other ways to tailor
the physicochemical characteristics of the polymer are using diﬀerent
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molecular weights of the polymer and changing the end group of the
polymer (Fredenberg et al., 2011a; Makadia and Siegel, 2011; Xu et al.,
2017).
A common method to achieve a biphasic pulsatile release proﬁle is
to develop a core-shell device. In such a device, a water-soluble core
containing the active component is encapsulated in a water-insoluble
biodegradable polymer shell to enable a delayed pulsatile release. This
device can be combined with an additional water-soluble outer layer
containing the active component, or can simply be co-injected with a
solution containing the active component to obtain the desired biphasic
pulsatile release proﬁle. A great disadvantage of core-shell devices is
that they require complicated production methods, amongst which
emulsiﬁcation, coating, multiple-compaction processes, and more re-
cently, a microfabrication production method named StampEd
Assembly of polymer Layers (Cleland, 1999; De Geest et al., 2009; Guse
et al., 2006; McHugh et al., 2017; Sungthongjeen et al., 2004; Tzeng
et al., 2018).
However, in 2000, Murakami et al. (2000) reported a device con-
sisting of a physical mixture of theophylline as a model drug and several
types of PL(G)A, simply prepared by a single compaction procedure.
This device exhibited the desired biphasic pulsatile release proﬁle. The
mechanism behind the biphasic pulsatile drug release from these PL
(G)A-based compacts, however, is not fully understood. Furthermore,
although the single compaction step seems a simple process, the authors
used a complicated emulsion technique to prepare polymeric nano-
particles for compaction and it is unclear whether similar results can be
obtained if larger polymer particles are used.
Based on literature, monolithic PL(G)A-based systems, such as the
physically mixed compacts described by Murakami et al. (2000) seem
less suitable for protein-based vaccines. An incomplete release of native
protein from monolithic devices due to protein instability is often ob-
served (Ghalanbor et al., 2012; Hines and Kaplan, 2013; van de Weert
et al., 2000). Major reasons for protein instability within these devices
are the formation of an acidic microclimate within the matrix and in-
compatibility of the polymer degradation products and proteins,
leading to aggregation and inactivation of the protein (Estey et al.,
2006; Kang and Schwendeman, 2002; Liu and Schwendeman, 2012;
Stanković et al., 2015). To overcome these issues, several excipients
(e.g. magnesium hydroxide and shellac) could potentially be in-
corporated to stabilize proteins within monolithic PL(G)A-based de-
vices (Duque et al., 2018; Zhu and Schwendeman, 2000). However,
polysaccharides, used as antigens in bacterial vaccines (e.g. pneumo-
coccal polysaccharide vaccine) (Weintraub, 2003) are more stable and
compatible with polymer degradation products. Therefore, a device
based on a physical mixture might be more interesting for the biphasic
delivery of a polysaccharide-based vaccine.
We hypothesize that compaction at a temperature below the Tg of
the polymer results in a porous compact, as the polymer is in the glassy
state. Once immersed into release medium with a temperature above
the Tg of the polymer, the drug can diﬀuse through the pores of the
compact, leading to a pulsatile burst release. However, at the same
time, the polymer undergoes a transition from the glassy state into the
rubbery state. Therefore, the pores of the compact are gradually closed
by viscous ﬂow of the polymer and further release is inhibited. After a
certain period of time, the polymer matrix ruptures, resulting in a
pulsatile boost release. To investigate this hypothesis, physically mixed
compacts based on theophylline as a model drug and various types of
PL(G)A were produced. The inﬂuence of the Tg of the polymer, the
temperature of compaction, the compression force, and the temperature
of the release medium on the release of theophylline from physically
mixed PL(G)A-based compacts were investigated. To investigate the
inﬂuence of the molecular weight of the incorporated drug on the re-
lease, blue dextran (BD) with a molecular weight of either 70 kDa or
2000 kDa was incorporated in the physically mixed compact. As bac-
terial vaccines are often polysaccharide-based, BD was also used to
mimic bacterial vaccines. Furthermore, core-shell compacts consisting
of a theophylline containing core tablet and a nonporous and a porous
shell composed of PLA with a high Tg were used as a control.
Understanding the mechanism behind the biphasic pulsatile release
could contribute to the further development of an eﬀective single-in-
jection vaccine.
2. Materials and methods
2.1. Materials
Poly(DL-lactic-co-glycolic acid) with a lactic:glycolic acid ratio of
50:50 and an intrinsic viscosity of 0.2 dL/g (PLGA5002), poly(DL-lactic
acid) with an intrinsic viscosity of 0.2 dL/g (PLA02), and 0.5 dL/g
(PLA05) were purchased from Corbion Purac Biomaterials (Gorinchem,
The Netherlands). Theophylline anhydrous was obtained from
Boehringer Ingelheim (Ingelheim am Rhein, Germany). BD with mole-
cular weights of 70 kDa and 2000 kDa were purchased from TdB
Consultancy (Uppsala, Sweden). Sodium dihydrogen phosphate and
disodium hydrogen phosphate were purchased from Merck (Darmstadt,
Germany). Sodium azide was obtained from Acros Organics (Geel,
Belgium). Inulin (4 kDa) with a degree of polymerization of 23 was a
generous gift from Sensus (Roosendaal, The Netherlands). Sodium
chloride was purchased from Fluka Chemie GmbH (Buchs,
Switzerland). Mannitol was purchased from Roquette (Nord-Pas-de-
Calais, France). All experiments were performed with Millipore, type 1
water.
2.2. Powder formulations for physically mixed compacts
For theophylline containing compacts, an aqueous solution con-
taining 5mg/ml theophylline and 50mg/ml inulin was prepared. Of
this solution, amounts of 2ml were transferred to 20ml vials. The so-
lutions were freeze-dried using a Christ Epsilon 2-4 LSC freeze-dryer
(Salm & Kipp, Breukelen, The Netherlands) at 0.220 mBar and a shelf
temperature of −35 °C for 24 h, after which the pressure was reduced
to 0.050 mBar while the shelf temperature was increased to 25 °C over a
period of 24 h. The obtained freeze-dried powder was then ground and
mixed with mannitol in a smooth agate mortar. This powder mixture
was then physically mixed with PLGA5002 or PLA02 in a smooth agate
mortar. Prior to mixing, PLGA5002 and PLA02 were ground with an
AR100 mill (Moulinex, Écully, France) and subsequently sieved with a
150 µm sieve. The resulting powder blends were used for the produc-
tion of the physically mixed PL(G)A-based compacts. The ﬁnal powder
formulation consisted of 4 wt-% freeze-dried theophylline and inulin (in
a 1:10 w/w ratio), 5.1 wt-% mannitol, and 90.9 wt-% polymer.
For BD containing compacts, an aqueous solution containing 5mg/
ml BD with either a molecular weight of 70 kDa or 2000 kDa and
6.4 mg/ml mannitol was prepared. Solutions were freeze-dried as de-
scribed above. The obtained freeze-dried powder was then physically
mixed with PLGA5002 with a particle size of ≤150 μm in a smooth
agate mortar. The ﬁnal powder formulation consisted of 4 wt-% BD
(with a molecular weight of either 70 kDa or 2000 kDa), 5.1 wt-%
mannitol, and 90.9 wt-% polymer.
2.3. Production of physically mixed PL(G)A-based compacts
The powder blends containing theophylline were compacted using a
hydraulic press (Hydro Mooi, Appingedam, The Netherlands) and an
oblong tablet die (6×2mm). Approximately 26mg of the powder
formulation described above was compressed at room temperature (RT)
with a compaction load of 7 kN and a compaction rate of 0.7 kN/s, or a
compaction load of 2.8 kN and a compaction rate of 0.28 kN/s. In both
cases the hold time was 10 s. To investigate the inﬂuence of tempera-
ture, the compact containing tablet die compressed at a compaction
load of 2.8 kN was stored in an oven for 1 h at 48 °C to allow viscous
ﬂow of the polymer. After removal from the oven, the compact was
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immediately re-compressed using the same settings as described above.
For BD containing compacts, approximately 27.5 mg of the powder
formulation was compressed at RT with a compaction load of either
3 kN and a compaction rate of 0.3 kN/s, or a compaction load of 9 kN
and a compaction rate of 0.9 kN/s. In both cases the hold time was 10 s.
These compaction loads were chosen to further investigate the inﬂu-
ence of compression force on the release proﬁle. Note that with the
speciﬁc oblong tablet die, three tablets were simultaneously prepared,
resulting in a compaction force per tablet that was three times lower
than the total compaction force.
2.4. Production of PLA core-shell compacts
First, PLA05 pellets were milled with a Pulverisette 14 (Fritsch
GmbH, Idar-Oberstein, Germany) at 6000–10,000 rpm and sieved with
a 200 µm sieve. To produce the core tablet, approximately 25mg of a
physical mixture consisting of 44 wt-% freeze-dried theophylline and
inulin (in a 1:10 w/w ratio) and 56wt-% mannitol was compressed in a
7mm diameter tablet die at a compaction load of 5 kN, a compaction
rate of 0.5 kN/s, and a hold time of 10 s. Subsequently, the core was
inserted into a 9mm diameter tablet die, in which ground PLA02 or
PLA05 was added as top layer (23.5mg) and as bottom layer (93mg).
The PLA02 or PLA05 shell was then compressed at a compaction load of
12.5 kN, a compaction rate of 1.25 kN/s, and a hold time of 10 s. To
investigate the eﬀect of heating on the release characteristics of PLA05
core-shell compacts, the same procedure was used except that com-
pression was at a compaction load of 5 kN, a compaction rate of 0.5 kN/
s, and a hold time of 10 s. Thereafter, the core-shell compact containing
tablet die was stored in an oven for 1 h at 80 °C to allow for suﬃcient
viscous ﬂow of the polymer. After removal from the oven, the core-shell
compact was immediately re-compressed using the same settings as
described above. The resulting core-shell compact had a shell thickness
of approximately 300 µm on top and 1000 µm at the bottom and the
sides.
2.5. Diﬀerential scanning calorimetry (DSC)
DSC measurements of PLGA5002, PLA02, and PLA05 were done
with a Q2000 diﬀerential scanning calorimeter (TA Instruments, New
Castle, DE, United States). Dry samples were weighed in open Tzero
pans at ambient conditions. The samples were preheated to a tem-
perature of 120 °C prior to scanning at a rate of 20 °C/min and a tem-
perature range of −20 °C to 90 °C. The same samples were used to
determine the Tg when moisturized. To achieve this, 40 µL of water was
added to the sample and the sample was moisturized over a period of
30min. The excess of water was subsequently removed. Finally, the pan
was hermetically sealed, after which the sample was cooled to -50 °C
and then heated at a rate of 20 °C/min to a temperature of 90 °C. Each
sample was measured directly and 2, 5, and 7.5 h after moisturizing. To
gain insight in the degradation process of PL(G)A, DSC measurements
were conducted on physically mixed theophylline containing
PLGA5002 compacts after diﬀerent exposure times to the release
medium. At predetermined time points, compacts exposed to the re-
lease medium at 37 °C were removed from the release medium and cut
to pieces using a scalpel. The samples were weighed in open Tzero pans
at ambient conditions and were ﬁrst preheated for 10min at a tem-
perature of 120 °C. After this preheating step, the samples were cooled
to −20 °C and then heated with a rate of 20 °C/min to 90 °C. The Tg
was deﬁned as the onset of the transition.
2.6. In vitro release of theophylline and blue dextran from physically mixed
PL(G)A-based compacts and PLA core-shell compacts
The in vitro release tests were performed in 20ml (for physically
mixed theophylline containing compacts) or 50ml (for core-shell
compacts) 100mM phosphate buﬀered saline (PBS) (pH 7.4)
supplemented with 0.02% (w/v) sodium azide. The temperature of the
release medium in the standard procedure was 37 °C. However, to in-
vestigate the inﬂuence of release medium temperature, physically
mixed compacts were immersed into release medium of either 4 °C, RT,
or 37 °C. The release medium was ﬁrst preheated or precooled to the
temperature at which the release was studied. The release studies were
performed in a shaking water bath (80 rpm) to allow refreshment of the
release medium at the surface of the compacts. Theophylline release
was measured with a UV–visible spectrophotometer (Thermo
Spectronic Unicam UV-540, Waltham, MA, United States) at
λ=272 nm and at λ=325 nm (reference wavelength). Sampling was
performed by taking 2.5–3ml of the release medium through a ﬂow-
through cuvette (L= 10mm) and returning the sample back to the
release medium. The in vitro release tests with BD containing compacts
were performed in 1ml release medium at a temperature of 37 °C. At
predetermined time points, samples of 0.9 ml were taken and 0.9 ml of
fresh preheated (37 °C) release medium was added to the vial to keep
the volume constant. The samples were centrifuged for 15min at
14,800 rpm and the supernatant was used to measure BD release at
λ=616 nm using a ﬂow-through cuvette (L= 50mm).
2.7. Scanning electron microscopy (SEM)
SEM images of physically mixed compacts were taken with a JEOL
6460 microscope (JEOL, Tokyo, Japan). To investigate the inﬂuence of
the compression force on surface porosity, SEM images of PLA02
compacts compressed at 2.8 kN and 7 kN were taken prior to release.
Theophylline containing PLA02 compacts were imaged after 3 days of
release at 4 °C, RT, or 37 °C. In addition, physically mixed PLA02
compacts were imaged after 4, 8, and 72 h of release at 37 °C. To gain
insight in the boost release, theophylline containing PLGA5002 com-
pacts were imaged after 18 days of exposure to the release medium.
Prior to imaging, incubated compacts were freeze-dried using the same
program as described above. The dry compacts were stuck on top of
double-sided adhesive carbon tape on aluminum disks and coated with
a 17 nm layer of gold in a JFC-1300 sputtering device ﬁtted with an
MTM-20 thickness controller system (JEOL, Tokyo, Japan). An accel-
eration voltage of 10 kV, a spot size of 25, and a Z-distance of 15mm
was used for all recordings.
2.8. Comparison of the release proﬁles
The release proﬁles were compared by using the similarity factor
(f2), which is calculated using the following equation (Shah et al., 1998;
Srinarong et al., 2009):
∑= ∗ + − ∗=
−f 50 log{[1 1/ n n (R T ) ] 100}2 t 1 t t 2
0.5
where n is the number of release sampling times, and Rt and Tt are the
average percentage drug released at each time point from the reference
formulation and the test formulation, respectively. The time point t= 0
was excluded and only one point after more than 85% drug release was
included, as recommended by Shah et al. (1998). If the f2 > 50, the
release proﬁles can be considered similar.
3. Results
3.1. Glass transition temperatures of the polymers
The Tg’s of PLGA5002, PLA02, and PLA05 were measured with DSC.
The average onset of the transition of two measurements were 31.6 °C,
33.5 °C, and 44.3 °C, respectively. Furthermore, moisturizing the poly-
mers with water reduced the Tg to 19.1 °C, 24.3 °C, and 37.1 °C, re-
spectively. The latter values were measured 5 h after moisturizing, this
was when the Tg reached a plateau value.
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3.2. In vitro release of theophylline from physically mixed PLGA5002- and
PLA02-based compacts
Fig. 1 shows the release at 37 °C of theophylline from compacts with
either a PLGA5002 or a PLA02 polymer matrix prepared at a compac-
tion load of 7 kN and RT. The physically mixed compacts released
56.6 ± 3.7% and 49.3 ± 2.9% of the total theophylline content
during the initial burst release, respectively. The remaining content was
released as a pulse after a lag phase. The lag phase was substantially
shorter for PLGA5002-based compacts (approximately 18 days) than for
PLA02-based compacts (approximately 50 days).
3.3. Eﬀect of compression force and heating on theophylline release from
PLA02-based compacts
Physically mixed compacts with PLA02 were compressed at 2.8 kN,
instead of 7 kN to study the eﬀect of a possibly more porous compact on
the burst release. Furthermore, compacts compressed at 2.8 kN were
heated in an oven set at 48 °C for 1 h in between two compaction
procedures to study the eﬀect of heating. A lower compression force
resulted in a visibly more porous surface of the compact (Fig. 2A and B),
but only in a minor increase in burst release (Fig. 2C). The burst release
was 55.8 ± 0.9% and 49.3 ± 2.9% for compacts compressed at 2.8 kN
and 7 kN, respectively. However, based on the f2, which was 63.3, the
two release proﬁles were found to be similar. Heating of the compact
resulted in a reduction of the burst release of theophylline from
55.8 ± 0.9% to 22.6 ± 5.8% (Fig. 3). The lag phase duration was
unaﬀected, and although a small fraction appeared to release during the
lag phase, most of the remaining theophylline was released as a pulse
after the lag phase. Based on the f2, which was 27.4, the two release
proﬁles were not similar.
3.4. Eﬀect of release medium temperature on theophylline release from
PLA02-based compacts
Physically mixed PLA02-based compacts compressed at a compac-
tion load of 7 kN and RT were set to release at 4 °C, RT, and 37 °C
(Fig. 4). At RT and below, all theophylline was released during the burst
in the ﬁrst 3 days, whereas at 37 °C, 51.1 ± 3.1% of theophylline was
released. In addition, based on the f2, which was 26.9, the release
proﬁles at 4 °C and RT were diﬀerent. SEM images from physically
mixed PLA02-based compacts containing theophylline directly after
compaction (Fig. 2B) and after 3 days of release at 4 °C, RT, and 37 °C
showed a noticeable diﬀerence in the surface structure of the compacts
(Fig. 5A–C). Directly after compaction, a rough, porous structure was
observed. After 3 days of release at 4 °C and RT, the compacts still
showed a rough, porous structure. However, after 3 days of release at
37 °C, the surface appeared to be completely smooth and nonporous.
Fig. 6A–C shows SEM images of PLA02 compacts after 4, 8, and 72 h of
release at 37 °C. After 4 and 8 h of release at 37 °C, a few pores can still
be seen on the surface of the compact. However, after 72 h, the compact
showed a smooth, nonporous surface.
3.5. Degradation of PLGA: DSC measurements after diﬀerent exposure
times to the release medium and boost release
Fig. 7A shows thermograms of theophylline containing PLGA5002-
based compacts compressed at 7 kN and RT after diﬀerent exposure
times to the release medium at 37 °C. The results clearly show that the
Fig. 1. Release of theophylline from physically mixed compacts with either a
PLGA5002 (grey) or a PLA02 (black) polymer matrix at 37 °C, prepared at a
compaction load of 7 kN and RT. Standard deviation is indicated (n=3).
Fig. 2. (A–C) SEM images (top view) of a physically mixed PLA02 compact
prepared at RT and a compaction load of 2.8 kN (A) and 7 kN (B) at a magni-
ﬁcation of 30× and the release of theophylline at 37 °C from these compacts
(2.8 kN (grey) and 7 kN (black)) (C). Standard deviation is indicated (n= 3).
Fig. 3. Release of theophylline at 37 °C from physically mixed PLA02 compacts
compressed at 2.8 kN that are either heated for 1 h at 48 °C (black) or not he-
ated (grey) during compaction. Standard deviation is indicated (n= 3).
Fig. 4. Release of theophylline from physically mixed PLA02 compacts pre-
pared at a compaction load of 7 kN and RT, at 4 °C (black), RT (light grey), and
37 °C (dark grey). Standard deviation is indicated (n= 3).
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Tg of the polymer decreased over time. Prior to exposure to the release
medium, the Tg was 32.8 °C. After 18 days of release, when the pulse
was observed for theophylline containing PLGA5002-based compacts
(Fig. 1), the Tg was found to be 27.0 °C. After 24 days of release at
37 °C, the Tg further decreased to 24.1 °C. Fig. 7B shows a SEM image of
a PLGA5002-based compact after 18 days of release at 37 °C. The image
clearly shows a ruptured compact.
3.6. In vitro release of BD from physically mixed PLGA5002-based
compacts
Fig. 8A and B shows the release at 37 °C of BD with a molecular
weight of 70 kDa (Fig. 8A) and 2000 kDa (Fig. 8B) from compacts with
a PLGA5002 polymer matrix prepared at RT and a compression force of
3 kN or 9 kN. A larger diﬀerence between the two compression forces
than previously (2.8 kN and 7 kN) was chosen to further investigate the
inﬂuence of compression force on the release proﬁle. Physically mixed
compacts compressed at 3 kN and 9 kN containing BD with a molecular
weight of 70 kDa released 58.4 ± 9.8% and 54.3 ± 6.1% of the total
BD content during the initial pulsatile burst release, respectively. Based
on the f2, which was 69.9, the two release proﬁles were similar. Phy-
sically mixed compacts compressed at 3 kN and 9 kN containing BD
with a molecular weight of 2000 kDa released 48.3 ± 4.1% and
53.8 ± 1.8% of the total BD content during the initial pulsatile burst
release, respectively. Based on the f2, which was 55.0, the release
proﬁles were similar. The release proﬁles of the diﬀerent BD molecular
weights (70 kDa and 2000 kDa) compressed at either 3 kN or 9 kN were
also similar, with f2 values of 51.7 and 78.8, respectively. The re-
maining content was released as a pulse after a lag phase. The lag phase
was approximately 21 days for both molecular weights of BD.
3.7. Eﬀect of a nonporous shell on the burst release
Three diﬀerent core-shell compacts were prepared by either omit-
ting the heating step with PLA02 or PLA05 as shell material and com-
pressing with a compaction load of 12.5 kN, or by heating at 80 °C for
1 h during compaction and compressing at a compaction load of 5 kN
with PLA05 as shell material. The non-heated PLA02 core-shell compact
exhibited a delayed release proﬁle without any initial burst release. The
lag time was approximately 40 days. All the theophylline was released
Fig. 5. (A–C) SEM images (top view) of a physically mixed PLA02 compact prepared at a compaction load of 7 kN and RT after 3 days of release at 4 °C (A), RT (B),
and 37 °C (C) at a magniﬁcation of 30×.
Fig. 6. (A–C) SEM images (top view) of a physically mixed PLA02 compact prepared at a compaction load of 7 kN and RT after 4 h (A), 8 h (B), and 72 h (C) of release
at 37 °C at a magniﬁcation of 30×.
Fig. 7. A and B DSC thermograms of a physically mixed PLGA5002 compact
prepared at a compaction load of 7 kN and RT after diﬀerent times of exposure
to the release medium at 37 °C (A) and SEM image (top view) of a physically
mixed PLGA5002 compact after 18 days of exposure to the release medium at
37 °C at a magniﬁcation of 30× (B).
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within 2 days from the non-heated PLA05 core-shell compact, however,
if the PLA05 core-shell compact was heated at 80 °C for 1 h, a delayed
release without any initial burst release was exhibited. The lag time was
approximately 100 days (Fig. 9).
4. Discussion
The compacts prepared at RT from a physical mixture of PLGA5002
or PLA02 and theophylline exhibited a biphasic pulsatile release proﬁle
at 37 °C, similar to the previous ﬁndings (Murakami et al., 2000)
(Fig. 1). Furthermore, the lag time could be adjusted by changing the
polymer composition, which is also in line with the previous study
(Murakami et al., 2000). These results imply that the release me-
chanism may be independent of the polymer particle size, as in the
study of Murakami et al. (2000) nanoparticles were used, while in the
present study more coarse particles were used. However, head-to-head
experiments should be performed to conﬁrm this. Not all compacts
exhibited a biphasic pulsatile release proﬁle. It was found that the re-
lease proﬁle was greatly dependent on the Tg of the polymer, the
temperature during compaction, and the temperature of the release
medium. If the temperature during compaction was below and the
temperature during release was above the Tg of the polymer, a biphasic
pulsatile release proﬁle was obtained with a 50–60% burst release and a
40–50% boost release. According to the results shown in this study, this
biphasic pulsatile release proﬁle can be attributed to the transition from
the glassy state into the rubbery state of the polymer, as will be made
clear in the following discussion.
As described by Fredenberg et al. (2011a) four release mechanism
should be considered when investigating drug release from a PL(G)A-
based device, namely: diﬀusion through water-ﬁlled pores, diﬀusion
through the polymer, osmotic pumping, and polymer erosion. During
compaction at RT, a porous matrix was formed, as conﬁrmed by SEM
for PLA02-based compacts (Figs. 2A and B). This porous structure is
typical for a glassy polymer and is caused by the relatively high Tg of
dry PLGA5002 and PLA02 of 31.6 °C and 33.5 °C, respectively. When
the compact is set to release at 37 °C, the polymer will heat up and
absorb water. As the Tg of the moisturized polymer is below environ-
mental temperatures, i.e. 19.1 °C for PLGA5002 and 24.3 °C for PLA02,
a transition from the glassy state into the rubbery state will occur. This
causes the polymer chains to become mobile and viscous ﬂow will close
the pores that were originally present after compaction (Fig. 5C). The
phenomenon of pore closure has been described in several other studies
(Fredenberg et al., 2011b; Kang and Schwendeman, 2007; Wang et al.,
2002; Yamaguchi et al., 2002). However, diﬀerent PL(G)A-based de-
vices were studied and therefore the mechanisms of pore closure may
be diﬀerent. Because pore closure of the physically mixed compacts was
not instantly (Fig. 6A–C), part of the drug could diﬀuse through the
pores of the compact before the pores were sealed, resulting in a pul-
satile burst release. The diﬀusion through pores has also been described
as a possible drug release mechanism from various other types of PL
(G)A-based devices in literature (Fredenberg et al., 2011a; Gao et al.,
2007; Yushu and Venkatraman, 2006; Zidan et al., 2006). This release
mechanism is further supported by the fact that the burst release was
reduced from 55.8 ± 0.9% to 22.6 ± 5.8% when the PLA02-based
compacts were heated for 1 h at 48 °C (a temperature above the Tg of
dry PLA02) prior to starting the release experiment (Fig. 3). A small
amount of burst release can be expected, as some of the dispersed drug
will be at or near the surface of the compact. The burst release was
followed by a lag phase, since the hydrophilic drug molecules were not
able to diﬀuse through the nonporous polymer matrix of the physically
mixed compacts.
To further support our hypothesis, a release experiment was per-
formed in which the release temperature was lowered to refrigerated
conditions (4 °C) or RT (Fig. 4). At these temperatures, the Tg of PLA02
is above the environmental temperature during release, and the
polymer does not transition into the mobile rubbery state. Conse-
quently, no pore closure occurred, as conﬁrmed by SEM (Fig. 5A and B).
Therefore, all the theophylline was released during the burst. At RT, the
burst release was faster than at refrigerated conditions, this is due to a
higher diﬀusion rate of theophylline through the porous compact to the
release medium at higher temperatures. These results show that the
temperature of the release medium aﬀects pore closure.
Although decreasing the compression force from 7 kN to 2.8 kN
resulted in a visibly more porous surface of the compact (Figs. 2A and
B), the release proﬁles from both compacts were similar (Fig. 2C).
Apparently, the initial porosity of the surface of the compact did not
inﬂuence the burst release. This may be explained by the fact that the
water soluble mannitol in the formulation acts as a pore former,
creating a more porous compact when immersed into the release
medium. As pore closure was not instantly (Fig. 6A–C), this led to a
rapid initial burst release, which was independent of the initial porosity
of the compact. It is known from literature that additives may act as
pore formers and aﬀect the structure of various PL(G)A-based devices
(Fredenberg et al., 2011a).
The Tg of PLGA-based compacts clearly decreased over time
Fig. 8. A and B Release of BD with a molecular weight of 70 kDa (A) or 2000 kDa (B) at 37 °C from physically mixed PLGA5002 compacts prepared at RT with a
compaction load of 3 kN (grey) or 9 kN (black). Standard deviation is indicated (n=3).
Fig. 9. Release of theophylline at 37 °C from core-shell compacts with a PLA02
shell that was non-heated and compressed at 12.5 kN (black), a PLA05 shell that
was non-heated and compressed at 12.5 kN (light grey), and a core-shell com-
pact with a PLA05 shell that was heated at 80 °C for 1 h and compressed at 5 kN
(grey). Standard deviation is indicated (n=3).
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(Fig. 7A). According to the Fox-Flory equation, the Tg decreases with a
decrease in molecular weight of the polymer (Fox and Flory, 1950;
Park, 1995). Therefore, these results indicate that the molecular weight
of the polymer decreases over time due to degradation. After 18 days of
release at 37 °C, the compact showed a ruptured surface (Fig. 7B),
which might be ascribed by the following mechanism. The dissolved
acidic byproducts of the degrading polymer are trapped in the polymer
matrix and accumulate over time. This accumulation possibly led to an
increase of the osmotic pressure within the compact, which has recently
been described by Mylonaki et al. (2018) for PLGA-based micro-
particles.
Eventually, the osmotic pressure within the compact may build up
to such an extent that it ruptured the compact, leading to the pulsatile
boost release. Such osmotic pressure induced rupturing of polymeric
matrices has been described in literature (Fredenberg et al., 2011a;
Kang and Schwendeman, 2007; Park, 1995).
Incorporation of BD with a molecular weight of 70 kDa or 2000 kDa
into the physically mixed compacts showed similar results as the
theophylline containing compacts (Fig. 8A and B). As with the theo-
phylline containing compacts, the compression force did not inﬂuence
the release proﬁle. However, the lag phase for BD containing physically
mixed compacts was approximately 3 days longer than with theophyl-
line containing compacts. This diﬀerence in lag time might be explained
by the diﬀerence in sampling procedure. These results indicate that
molecular weight does not inﬂuence the release. The independence of
molecular weight supports the fact that the compact ruptures, possibly
due to a build-up in osmotic pressure.
Finally, using PLA05, a polymer with a higher Tg (onset at 37.1 °C
when moisturized), resulted in all of the theophylline being released
during the initial burst (Fig. 9). This even occurred despite the fact that
a core-shell conﬁguration was used, resulting in a thicker polymer layer
for the theophylline to diﬀuse through. This is due to the fact that the
Tg of moisturized PLA05 is slightly above the environmental tem-
perature during release. However, heating the PLA05 core-shell com-
pact for 1 h at 80 °C (a temperature far above the Tg) prior to release
reduced the initial burst release to zero. This is because there was no
theophylline at or near the surface and the shell surrounding the core
becomes nonporous upon the heating step. Non-heated PLA02 core-
shell compacts exhibited a delayed release without any initial burst
release. This can be explained by the fact that the Tg of moisturized
PLA02 (24.3 °C) is below the environmental temperature during re-
lease.
Understanding the mechanism behind the biphasic pulsatile release
from physically mixed compacts could contribute to further develop
single-injection vaccines. The release proﬁle can be tailored to speciﬁc
therapies, opening up new ways to optimize the protection against
various pathogens. Speciﬁcally, a device based on a physical mixture
might be interesting for the development of a single-injection poly-
saccharide-based vaccine, as it is possible to successfully incorporate
polysaccharides into the compact. Because the release proﬁle is not
inﬂuenced by the molecular weight of the incorporated drug, multiple
antigens with diﬀerent molecular weights can be incorporated into the
same device.
5. Conclusion
As described by Murakami et al. (2000), a biphasic pulsatile release
could be obtained from a physically mixed PL(G)A-based compact.
However, the mechanism behind this biphasic pulsatile release proﬁle
was previously not fully understood. We found that the pulsatile release
was greatly inﬂuenced by the Tg of the polymer. After compaction, a
porous compact was formed from which one part of the active com-
ponent released instantly by diﬀusion through the pores of the compact.
However, if a polymer with a Tg below the environmental temperature
was used, the pores closed due to viscous ﬂow of the polymer and re-
lease of the active component was inhibited, since the hydrophilic drug
is not able to diﬀuse through the nonporous polymer matrix. Instead,
the burst release was followed by a lag time and a second pulsatile
release (booster) was obtained. This pulsatile boost release was not
inﬂuenced by the molecular weight of the incorporated drug, as it was
caused by rupturing of the compact, possibly due to a build-up of os-
motic pressure. Furthermore, the initial porosity of the compact did not
inﬂuence the release proﬁle. The physically mixed compact prototype
might be interesting for the development of a single-injection poly-
saccharide-based vaccine, as BD could successfully be incorporated into
the compact.
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